The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes. It was founded in 1909 as a unit of University College London (UCL), and became an independent charity in 2002. The Institute is committed to improving the prevention, diagnosis and treatment of cancer through world-leading basic and translational research.
The Institute has over 2,000 staff, including more than 1,000 scientists working across nine divisions:
* Cell Biology & Epigenetics
* Cancer Therapeutics
* Genetics & Epigenetics
* Immunology & Inflammation
* Infection & Immunity
* Metabolism & Development
* Molecular Oncology
* Population Sciences
and the Clinical Trials Unit. The ICR also houses three centres: the Centre for Drug Development, the Breast Cancer Now Toby Robins Research Centre and The Target Discovery Institute. In addition, there are four cross-cutting platforms – Biological Services, Genomics, Bioinformatics and Target Validation – which provide vital support for all of the ICR’s work. The ICR has an annual income of c£180 million (2019/20). Of this total around 80% comes from external sources including government grants (both from UKRI and other public bodies), philanthropy and commercial partners.
English 
Español 
Русский 
Deutsch 
Français 
Português